CX Institutional Buys 7,279 Shares of Danaher Corporation $DHR

CX Institutional grew its stake in Danaher Corporation (NYSE:DHR – Free Report) by 21.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,221 shares of the conglomerate’s stock after buying an additional 7,279 shares during the period. CX Institutional’s holdings in Danaher were worth $7,852,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Main Street Group LTD acquired a new stake in Danaher during the 1st quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new position in shares of Danaher in the 3rd quarter worth approximately $25,000. Elevated Capital Advisors LLC acquired a new position in shares of Danaher in the 4th quarter worth approximately $26,000. WFA of San Diego LLC bought a new stake in shares of Danaher in the 2nd quarter valued at $26,000. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Danaher during the fourth quarter worth $27,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Get Danaher alerts:

Danaher Price Performance

DHR stock opened at $197.78 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company’s 50-day moving average is $188.87 and its 200-day moving average is $195.08. The stock has a market capitalization of $139.03 billion, a PE ratio of 35.13, a price-to-earnings-growth ratio of 2.43 and a beta of 0.78. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the company posted $0.77 EPS. The firm’s revenue was up 5.5% compared to the same quarter last year. Equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Robert W. Baird lowered their target price on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Royal Bank Of Canada increased their price target on Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a report on Wednesday, July 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 price objective on shares of Danaher in a research report on Tuesday, April 21st. Finally, Citigroup started coverage on Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Check Out Our Latest Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Recommended Stories

• Five stocks we like better than Danaher
• SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
• Why Rare Earth Processing Could Be the Real 2027 Opportunity
• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
• TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.